Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (November 2021)
17 slides from Osteopore's investor presentation, Nov 22, 2021
Slide 1: Empowering Natural Tissue Regeneration
For personal use only Empowering Natural Tissue Regeneration INVESTOR PRESENTATION NOVEMBER 2021 INVESTOR PRESENTATION OSTEOPORE.COM
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection wit h any potential investment in the Company. You should not t
Slide 3: Novel Implants That Facilitate Bone & Tissue Regeneration
NOVEL IMPLANTS THAT FACILITATE BONE & TISSUE REGENERATION For personal use only Breakthrough Technology Value Creating World first biomimetic implants A clear focus on developing developed in collaboration with revenue streams to deliver high leading research institutions and margin growth underlies
Slide 4: ASX Regenerative Medtech Landscape
For personal use only ASX REGENERATIVE MEDTECH LANDSCAPE Polynovo Avita Regenerative medicine treats injuries and diseases by (ASX: PNV) (ASX: AVH) harnessing the body’s own regenerative capabilities $988.77m $565.80m to regrow, repair or replace damaged or diseased cells, organs or tissues. Cynata
Slide 5: Strong Focus on Collaborative Partnerships
For personal use only GROUND-BREAKING HOSPITALS AND UNIVERSITY RESEARCH HEALTHCARE INSTITUTES STRONG FOCUS ON COLLABORATIVE PARTNERSHIPS Product development partnerships SCIENCE AND INDUSTRY PARTNERS LEADERS IN LIFE SCIENCES Cross-promotion sales agreements MANUFACTURING CAD & AI TECHNOLOGY Combinin
Slide 6: Foundational Platform to Empower Tissue Regeneration
FOUNDATIONAL PLATFORM TO EMPOWER TISSUE REGENERATION For personal use only Novel process to regenerate bone Proven applications across the entire body IMPLANT DRAWS IN BLOOD CRANIOFACIAL & ORAL MAXILLOFACIAL 1 Multiple products that support craniofacial surgeries for Biomimetic microstructures allow
Slide 7: Competitive Strengths Leveraged by Solving Unmet Clinical Needs
COMPETIVITE STRENGTHS LEVERAGED BY SOLVING UNMET CLINICAL NEEDS For personal use only TRADITIONAL PROCEDURES BONE GRAFT Potential for infection and US$3.9bn lasting pain at harvest site Bone Graft Substitutes Highly customisable Proven to be Unlikely Market by 2025 to biomimic different effective in
Slide 8: Strong Product Pipeline with Significant Addressable Markets
STRONG PRODUCT PIPELINE WITH SIGNIFICANT ADDRESSABLE MARKETS For personal use only PRODUCTS FOR INDIVIDUAL FY22 FY23 FY24 FY25 SURGICAL SUBSPECIALTY APPLICATIONS REGULATORY CLEARANCE FY20 FY21 MARKET OPPORTUNITY SALES AVENUE Burr Hole Procedure EXISTING COMMERCIAL PRODUCTS Neurological Shunt Procedu
Slide 9: Anticipated Regulatory Milestones
ANTICIPATED REGULATORY MILESTONES Q1 - Q2 CY22 Q3 – Q4 CY22 CY23 – CY24 For personal use only China Europe China USA China ▪ [expected] Guangdong-Hong Kong-Macau ▪ Lodge EU application for Custom Made ▪ Initiate market entry process for NMPA ▪ [expected] US 510(k) clearance for ▪ [expected] NMPA app
Slide 10: Post-COVID Growth Strategy
POST-COVID GROWTH STRATEGY For personal use only Horizon 1: Next 12 to 18 months Horizon 2: Next 18 to 36 months Horizon 3: >36 months Grow revenue across current Launch additional products Develop and commercialise commercial product line for new areas of treatment breakthrough technology Strategy
Slide 11: Encouraging Tailwinds Expected to Drive Product Uptake
ENCOURAGING TAILWINDS EXPECTED TO DRIVE PRODUCT UPTAKE For personal use only POST-COVID ON-GROUND OPPORTUNITIES PENT-UP DEMAND Vaccination rates are Medical trade shows are starting to Fully dedicated sales team ready to take expected to improve as revert back to “in-person” which will advantage of
Slide 12: New Applications
NEW APPLICATIONS DENTAL For personal use only ORTHOPAEDIC Early clinical Early clinical Application Market access status Market growth strategy Application Market access status Next evolution investigation investigation ▪ Leverage approval in Singapore to drive ▪ Completed First- sales in ASEAN in-h
Slide 13: New Technology Accelerating Bone Regeneration
NEW TECHNOLOGY For personal use only ACCELERATING BONE REGENERATION REGENERATION OF OTHER TISSUE Osteopore is investigating the viability of Osteopore has successfully completed animal incorporating compounds to produce novel trials for knee cartilage regeneration, and the polycaprolactone polymer c
Slide 14: Financials
FINANCIALS REVENUE MARGINS For personal use only CAPITAL STRUCTURE • Despite the considerable disruption COVID- • Osteopore® continues to work towards Shares on Issue A 117.2m 19 has caused the healthcare eco-system, maintaining and improving its margins. Osteopore® has continued generate consistent
Slide 15: Key Takeaways
KEY TAKEAWAYS For personal use only Regenerative medical device Global expansion underway with company with proven, superior Fully trained and dedicated regulatory clearance and products that empower tissue sales team expected to drive distribution partners secured in regeneration. growth in the nea
Slide 16: For personal use only
For personal use only Carl Runde Chief Financial Officer M +61 400 118 017 E: carl_runde@osteopore.com INVESTOR PRESENTATION OSTEOPORE.COM 16
Slide 17: Sources
SOURCES For personal use only 1 Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K., & Giannoudis, P. V. (2011). Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury , 42, S3-S15. 2 Younger, E. M., & Chapman, M